^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Delytact (teserpaturev)

    i
    Other names: DS-1647, HSV-1-G47 delta, G47 delta, DS 1647, G47 delta oncolytic virus therapy, G47 Δ oncolytic virus therapy, DS1647
    Company:
    Daiichi Sankyo
    Drug class:
    Apoptosis stimulant
    Related drugs:
    over1year
    Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models. (PubMed, Mol Ther Oncolytics)
    We investigate the usefulness of administering G47Δ (teserpaturev), a triple-mutated oncolytic herpes simplex virus type 1, prior to resection...G47Δ therapy caused increased number of tumor-infiltrating CD8 and CD4 cells, increased F4/80 cells within the residual tongues, and increased expression of immune-related genes in and around the tumor. These results imply that neoadjuvant use of G47Δ is useful for preventing local recurrence after tongue cancer surgery.
    Preclinical • Journal • Oncolytic virus
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Delytact (teserpaturev)
    over1year
    Drugs under Development (Neurosurgery) (PubMed, Brain Nerve)
    "Delytact" is a viral-gene therapy that targets malignant brain tumors, such as malignant gliomas, while "Stemirac" targets against spinal contusion via self-mesenchymal implantation. Both are permitted clinical arsenals in Japan.
    Journal • Surgery
    |
    Delytact (teserpaturev)